Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.
Little information is available on the disposition of prednisolone in kidney transplant patients and whether correlations exist between the pharmacokinetics and therapeutic or toxic effects of this drug. The present study was designed to determine the pharmacokinetics of prednisolone in six noncushingoid and six cushingoid transplant recipients. The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h). However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters). In addition, the availability of prednisolone after oral prednisone administration was considerably variable (overall range, 27-108%) and was not significantly different between the two groups. Thus, in kidney transplant patients it appears that the plasma clearance and volume of distribution of prednisolone may distinguish between noncushingoid and cushingoid patients.
D000328:Adult; D002648:Child; D003480:Cushing Syndrome / Q000139:chemically induced*; D005260:Female; D006207:Half-Life; D006801:Humans; D016030:Kidney Transplantation; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000097:blood*; D011241:Prednisone / Q000009:adverse effects*; D014184:Transplantation, Homologous
D011239:Prednisolone; D011241:Prednisone